Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone‐releasing hormone therapy: prognostic significance?
- 11 February 2010
- journal article
- Published by Wiley in BJU International
- Vol. 105 (5) , 648-651
Abstract
Study Type – Prognosis (case series) Level of Evidence 4 OBJECTIVE: To determine if the testosterone level achieved with androgen‐deprivation therapy (ADT) is directly related to survival and risk of death in men with metastatic prostate cancer, as agonistic analogues of luteinizing hormone‐releasing hormones (LHRH) are indicated for palliative treatment of these patients, but there is no consensus about the utility of serum testosterone measurements during the follow‐up, and their possible prognostic value. PATIENTS AND METHODS: We retrospectively reviewed 129 consecutive patients with a histological diagnosis of metastatic bony‐only prostate cancer and previously untreated with ADT. They were treated with 3 months of goserelin. Testosterone and prostate‐specific antigen (PSA) levels were measured in all patients every 3 months for the duration of the follow‐up. The following variables were recorded: age, stage, Gleason score, basal PSA level, basal testosterone level, PSA nadir, time to PSA nadir, testosterone after 6 months, testosterone nadir and time to testosterone nadir. Data were analysed using Cox’s proportional hazards models, with the primary endpoint being cancer‐specific survival. RESULTS: The mean ( sd ) basal PSA level was 185.8 (344.1) ng/mL, and the mean nadir PSA level 2.7 (8.6) ng/mL. The mean testosterone levels at baseline, 6 months and the nadir were 440 (200), 40 (40) and 21 (15) ng/dL. With a mean follow‐up of 47.5 (29.7) months, 71 patients were dead (55%) and 78 were alive (45%) at the time of analysis. Statistical analysis using Cox’s model showed that in these patients the risk of death was directly correlated not only to Gleason score ( P < 0.01) and to the 6‐month PSA level ( P < 0.01), but also to the 6‐month serum testosterone level (hazard ratio 1.32, P < 0.05). CONCLUSION: These results suggest a direct correlation between the risk of death and testosterone levels achieved during ADT. Based on the present results, lowering the testosterone level as much as possible should be the goal of ADT in patients with metastatic prostate cancer, as this might affect patient survival.Keywords
This publication has 20 references indexed in Scilit:
- Sex Hormones Unrelated to Prostate Cancer RiskJNCI: Journal of the National Cancer Institute, 2008
- Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation TherapyJournal of Urology, 2007
- Absolute Prostate-Specific Antigen Value After Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162)Journal of Clinical Oncology, 2006
- Expert Opinion on Optimal Testosterone Control in Prostate CancerEuropean Urology Supplements, 2005
- Is Prostate-Specific Antigen a Valid Surrogate End Point for Survival in Hormonally Treated Patients With Metastatic Prostate Cancer? Joint Research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca PharmaceuticalsJournal of Clinical Oncology, 2005
- Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone?European Urology Supplements, 2005
- 218 Failure of luteinizing hormone releasing hormone agonist therapy to achieve castration. Does it exist?European Urology Supplements, 2004
- FAILURE TO ACHIEVE CASTRATE LEVELS OF TESTOSTERONE DURING LUTEINIZING HORMONE RELEASING HORMONE AGONIST THERAPY: THE CASE FOR MONITORING SERUM TESTOSTERONE AND A TREATMENT DECISION ALGORITHMJournal of Urology, 2000
- Long-Term Efficacy and Safety of Nilutamide Plus Castration in Advanced Prostate Cancer, and the Significance of Early Prostate Specific Antigen NormalizationJournal of Urology, 1997
- A New Long Acting Formulation of the Luteinizing Hormone-Releasing Hormone Analogue, Goserelin: Results of Studies in Prostate CancerJournal of Urology, 1996